DOCSLIB.ORG

Stilbestrol Diphosphate on Serum Hormonal Levels in Patients with Hormone-Refractory Prostate Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Stilbestrol Diphosphate on Serum Hormonal Levels in Patients with Hormone-Refractory Prostate Cancer Endocrine Journal 1999, 46 (5), 659-664 Effects of Intravenous Administration of High Dose-Diethyl- stilbestrol Diphosphate on Serum Hormonal Levels in Patients with Hormone-Refractory Prostate Cancer SATOSHI KITAHARA, HIROSHI UMEDA, MASATAKA YANO, FUMITAKA KOLA, SHUHEI SUMI, HIDEO MORIGUCHI, YOSHIKATSU HOSOYA, MIKIHIKO HONDA AND KENICHIRO YOSHIDA Department of Urology, Dokkyo University School of Medicine, Mibu, Tochigi 321-02, Japan Abstaract. The objective of this study was to elucidate the mechanism underlying the further suppression of serum testosterone (T) by diethylstilbestrol diphosphate (DES-DP) in patients with prostate cancer refractory to hormonal treatment. These patients received an LHRH agonist with or without a non-steroidal androgen-receptor blocker or a gestagen before DES-DP. We measured serum levels of total and free T, dihydrotestosterone (DHT), estradiol (E2), dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone (DHEA), androstenedione, cortisol, al- dosterone before and during intravenous administration of high doses of DES-DP (500 or 1000 mg/day). DES-DP administration suppressed the serum levels of FSH (p=0.04) and total T (p=0.02), and eliminated free T (p =0.04) and E2 (p = 0.04) from serum, while reducing serum DHEA-S to approximately two-thirds of the pretreatment level (p=0.03). In contrast, serum levels of SHBG (p=0.02) and cortisol (p=0.02) were markedly increased after DES-DP administration. The latter had no significant effect on serum levels of LH, DHT, ACTH, 17a-hydrox- ypregnenolone, 17a-hydroxyprogesterone, DHEA, androstenedione, or aldosterone. The results suggest that the potent suppression of circulating total T by DES-DP is caused, in part, by the inhibitory effect of DES-DP on serum DHEA-S level. In most patients, high-dose DES-DP treatment completely suppressed the serum level of free T, while possibly elevating serum SHBG and decreasing serum total T. The mechanisms that maintain the serum level of serum DHT during DES-DP treatment require further elucidation. Key words: Prostate cancer, DES-DP, Testosterone, Dihydrotestosterone, DHEA-S, SHBG (Endocrine Journal 46: 659-664, 1999) APPROXIMATELY one-third of the patients with The administration of synthetic estrogens may be prostate cancer have clinical metastases when initially of benefit in patients with hormone-refractory diagnosed. Patients with advanced prostate cancer prostate cancer, although the duration and the first undergo medical or surgical castration in order benefit are limited [4, 5]. The mechanisms for these to reduce the serum levels of testosterone (T). Most beneficial effects were not known until recently, of these patients show some improvement after when a direct cytotoxic effect of diethylstilbestrol testicular androgen ablation [1] . However, almost diphosphate (DES-DP) on prostate cancer cells was all patients with an initially good response to such reported in vitro [6]. We previously showed that a therapy relapse and die within a few years [2]. therapeutic per os dose of DES-DP, a synthetic Their condition is termed hormone-refractory [3]. estrogen, suppresses serum total T to undetectable levels. The effect is significantly stronger than that of surgical castration or of the administration Received: January 5, 1999 of an LH-RH agonist [7]. We presume a potent Accepted: May 24, 1999 suppressive effect on serum T might be one of the Correspondence to: Dr. Satoshi KITAHARA, Department of mechanisms of DES-DP action in patients with Urology, Koshigaya Hospital, Dokkyo University School of Medicine, 2-1-50, Minami-Koshigaya, Koshigaya, Saitama hormone- refractory prostate cancers. Such cancer 343-8555, Japan is able to proliferate even at a level of serum T fol- 660 KITAHARA et al. lowing induction of castration, approximately 5% of The patients were weighed daily. Blood samples serum T level before castration. were collected at 0600-0800 h on day 1 to 2 wk before Adrenal androgens are thought to be the source of the beginning of treatment and again on the last day serum T following surgical or medical castration. of the treatment, with the patient's informed consent. We hypothesized that DES-DP might affect the pathway of steroid biosynthesis or its metabolism. Hormone assays Accordingly, in the present study, we measured se- rum levels of several hormones including adrenal Serum and plasma prepared from blood samples steroids and sex hormone-binding globulin (SHBG) were stored frozen at -80°C until assayed. All in patients with hormone refractory prostate cancer, circulating hormones in serum were measured by before and during the intravenous administration of radioimmunoassay in this study; i.e., ACTH, LH, large doses of DES-DP in an effort to elucidate the FSH, aldosterone, androstenedione, cortisol, 17a- mechanism of suppression of serum T by DES-DP. hydroxypregnenolone, 17a-hydroxyprogesterone, de- hydroepiandrosterone (DHEA), dehydroepian- drosterone sulfate (DHEA-S), free and total Subjects and Methods testosterone (T), and estradiol (E2). Sex hormone- binding globulin (SHBG) was measured by an im- Patient characteristics munoradiometric assay. The intraassay CV varied from 2.5% in LH to 17% for 17a-hydroxyprogester- Profiles of our seven patients are shown in Table 1. one, while the interassay CV varied from 2.1% in LH These Japanese men, aged 53 to 93 years, had been to 20% for 17a-hydroxyprogesterone. diagnosed as having advanced prostate cancer with bone metastasis and had been treated with an LH-RH Statistical analysis agonist, gosereline acetate (Zeneca Japan Phar- maceutical Co. Ltd., Tokyo) or leuprorelin acetate Data are expressed as mean±SD. The effects of (Takeda Pharmaceutical Co. Ltd., Osaka), with or DES-DP were confirmed by the Wilcoxon signed- without an anti-androgen (chlormadinone acetate, a rank (paired) test using Stat View (statistics software synthetic progesterone; Teikoku Hormone Mfg. Co., from Abacus Concepts, Inc., Berkeley, CA). For Ltd., Tokyo) or hydroxyflutamide, a non-steroidal convenience in statistical analysis, an undetectable androgen blocker (Nikon Kayaku Co. Ltd., Tokyo). level was considered to be the lower limit of detec- These patients had initially shown an improvement tion. A level of p <0.05 was accepted as statistically on such treatment but had relapsed 4 to 24 months significant. later. The relapse was confirmed by determination of serum levels of prostatic acid-phosphatase (PAP) or prostatic specific antigen (PSA), computerized Results tomography (CT) scans, and bone scintigraphy. Most patients were experiencing bone pain related Edema caused one patient to discontinue the to progressive bone metastases. treatment on the 14th day, and two patients deve- loped loss of appetite, but were able to continue Clinical protocol therapy (Table 1). In the 7 patients in whom the data were evaluative, no significant difference was ob- Each patient received DES-DP (Honvan: Kyorin served in circulating levels of the hormones and Pharmaceutical Co. Ltd., Tokyo) at a daily dose of SHBG measured for the three androgen-deprivation 1000 mg, sometimes reduced to 500 mg, based on therapy, that is, an LHRH agonist, an LHRH body weight and cardiovascular status. DES-DP, agonist with chlormadinone acetate, or an LHRH 250 mg or 500 mg, was freshly diluted in 250 mL of agonist with hydroxyflutamide (Tables 1-5). There- 5% dextrose and infused for 3 hours twice daily. A fore, all three androgen ablation therapies were con- dose of 81 mg acetylsalicylic acid was given orally sidered to exert similar effects on the hormonal everyday during the treatment to prevent thrombosis. milieu. SERUM HORMONAL CHANGES BY DES-DP 661 Table 1. Characteristics of patients with hormone-refractory prostate cancer who received high-dose intravenous diethylstil- bestrol diphosphate Table 2. Serum levels of hormones and SHBG before and during diethylstilbestrol diphosphate treatment in patients with hormone-refractory prostate cancer Table 3. Serum levels of pituitary hormones before and during diethylstilbestrol diphosphate treatment in the patients with hormone-refractory prostate cancer 662 KITAHARA et al. Table 4. Serum levels of steroids before and during diethylstilbestrol diphosphate treatment in patients with hormone-refractory prostate cancer Table 5. Serum levels of adrenal androgens before and during diethylstilbestrol diphosphate treatment in patients with hor- mone-refractory prostate cancer With high dose DES-DP, serum free and total T with previous androgen ablation therapies (Tables 4, (free: p = 0.042, total: p = 0.018) and E2 (p = 0.043) 5). Serum levels of 17a-hydroxyprognenolone, 17a- decreased and serum SHBG (p = 0.0l 8) increased hydroxyprogesterone, DHEA, androstenedione and significantly compared with previous treatments aldosterone appeared to be unaffected by DES-DP (Table 2). Serum free T was not detected except for treatment (Table 4, 5). one patient with DES-DP treatment, while no signifi- cant change in serum DHT levels was observed with DES-DP treatment (Table 2). Discussion For pituitary hormones, serum FSH decreased significantly (p = 0.042) and both LH and ACTH The endocrine effect of exogenous estrogens on showed no change during DES-DP administration serum T is thought to be due to suppression of the (Table 3). serum level of LH, i.e., acting via a negative feedback For serum steroids which are thought to be mainly mechanism [8, 9] . As we observed in the present from the adrenal, DES-DP treatment increased cor- study and have previously reported, not only an tisol (p = 0.018) and decreased DHEA-S (p = 0.034) LH-RH agonist but also therapeutic doses of DES- approximately one third significantly in comparison DP reduce the serum level LH to an undetectable SERUM HORMONAL CHANGES BY DES-DP 663 level, although serum levels of T are suppressed more via androstenediol might have been activated by the strongly by DES-DP than by an LH-RH agonist or administration of DES-DP. The existence of a by bilateral orchiectomy or by combined androgen similar phenomenon has been confirmed in the blockade with an LH-RH agonist and an androgen prostate following castration [8, 14, 15].
Load more

Recommended publications
  • Prnu-BICALUTAMIDE
    PRODUCT MONOGRAPH PrNU-BICALUTAMIDE Bicalutamide Tablets, 50 mg Non-Steroidal Antiandrogen NU-PHARM INC. DATE OF PREPARATION: 50 Mural Street, Units 1 & 2 October 16, 2009 Richmond Hill, Ontario L4B 1E4 Control#: 133521 Page 1 of 27 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS....................................................................................... 4 ADVERSE REACTIONS......................................................................................................... 5 DRUG INTERACTIONS ......................................................................................................... 9 DOSAGE AND ADMINISTRATION ................................................................................... 10 OVERDOSAGE...................................................................................................................... 10 ACTION AND CLINICAL PHARMACOLOGY.................................................................. 10 STORAGE AND STABILITY............................................................................................... 11 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • Supraphysiological Doses of Performance Enhancing Anabolic-Androgenic Steroids Exert Direct Toxic Effects on Neuron-Like Cells
    ORIGINAL RESEARCH ARTICLE published: 09 May 2013 CELLULAR NEUROSCIENCE doi: 10.3389/fncel.2013.00069 Supraphysiological doses of performance enhancing anabolic-androgenic steroids exert direct toxic effects on neuron-like cells John R. Basile1,2, Nada O. Binmadi 1,3, Hua Zhou1, Ying-Hua Yang1, Antonio Paoli 4 and Patrizia Proia1,5* 1 Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, Baltimore, MD, USA 2 Marlene and Stuart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA 3 Department of Oral Basic and Clinical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia 4 Department of Biomedical Sciences, University of Padova, Padova, Italy 5 Department of Sports Science (DISMOT), University of Palermo, Palermo, Italy Edited by: Anabolic-androgenic steroids (AAS) are lipophilic hormones often taken in excessive Chao Deng, University of quantities by athletes and bodybuilders to enhance performance and increase muscle Wollongong, Australia mass. AAS exert well known toxic effects on specific cell and tissue types and organ Reviewed by: systems. The attention that androgen abuse has received lately should be used as an Agata Copani, University of Catania, Italy opportunity to educate both athletes and the general population regarding their adverse Aram Megighian, University of effects. Among numerous commercially available steroid hormones, very few have been Padua, Italy specifically tested for direct neurotoxicity. We evaluated the effects of supraphysiological *Correspondence: doses of methandienone and 17-α-methyltestosterone on sympathetic-like neuron cells. Patrizia Proia, Department of Sports Vitality and apoptotic effects were analyzed, and immunofluorescence staining and Science (DISMOT), University of Palermo, Via Eleonora Duse 2, western blot performed.
    [Show full text]
  • Anabolic Androgenic Steroids (AAS) at Elevated Concentration Can Alter the Expression and Function of Neurotransmitter Systems and Contribute to Neuronal Cell Death
    ALMA MATER STUDIORUM UNIVERSITÀ DEGLI STUDI DI BOLOGNA Dottorato di Ricerca in Biotecnologie Cellulari e Molecolari XX CICLO Settore scientifico disciplinare BIO14 GENOMIC AND NON GENOMIC EFFECTS OF ELEVATED CONCENTRATION OF ANABOLIC STEROIDS IN HUMAN NEURONAL CELLS Presentata da: Dr. Goffredo Guarino Coordinatore Chiar.mo Prof. Relatore Chiar.mo Prof. Lanfranco Masotti Santi Spampinato ANNO ACCADEMICO 2006-2007 2 INDEX Abstract Chapter 1 – Anabolic androgenic steroid AAS abuse pag. 7 Testosterone structural modification pag. 9 Nandrolone pag.12 Synthesis and Metabolism pag.12 Mechanism of action pag.14 Androgen receptor pag.15 Physiological effects of AAS pag.18 Therapeutic use of AAS pag.19 Side effect of AAS pag.21 Androgen and Brain pag.22 Neurosteroids pag.23 In vivo and in vitro studies pag.23 References pag.27 Chapter 2. – Mu opioid receptor Opioid receptor ..pag.33 Receptor structure and function .pag.37 Physiological and Pharmacological action of opioid system .pag.40 Opioid endogenous peptides .pag.40 3 Analgesia .pag.41 Tolerance and dependence .pag.43 Side effects of acute opioid application pag.45 References pag.47 Chapter - 3. Neuronal cell death Apoptosis pag.50 Apoptosis in neurodegeneration pag.53 Androgen steroids and neuronal cell death pag.57 Sigma receptors and apoptosis pag.59 References pag.60 Aim of the Research Chapter - 4. Materials and Methods . Cell Cultures. pag.66 Semiquantitative real-time polymerase chain reaction pag.67 Western blotting pag.69 Radioligand Binding assay pag.70 Cell viability assays pag.71 Plasmid costruction pag.71 Cell trasfection and report gene assay pag.72 Immunocitochemistry pag.72 Caspase-3 activity pag.73 4 Statistical Analysis pag.73 References pag.74 Chapter - 5.
    [Show full text]
  • 203415Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 203415Orig1s000 PHARMACOLOGY REVIEW(S) MEMORANDUM Xtandi (enzalutamide) Date: August 22, 2012 To: File for NDA 203415 From: John K. Leighton, PhD, DABT Acting Director, Division of Hematology Oncology Toxicology Office of Hematology and Oncology Products I have examined pharmacology/toxicology supporting review of Dr. Brian Chiu and labeling and secondary memorandum provided by Dr. Palmby. I concur with Dr. Palmby’s conclusion that Xtandi may be approved and that no additional nonclinical studies are needed for the proposed indication. Reference ID: 3178425 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- JOHN K LEIGHTON 08/22/2012 Reference ID: 3178425 MEMORANDUM Date: August 20, 2012 From: Todd R. Palmby, Ph.D. Acting Pharmacology/Toxicology Supervisor Division of Hematology Oncology Toxicology (DHOT) Office of Hematology and Oncology Products (OHOP) To: File for NDA 203415 XTANDI (enzalutamide) Re: Approvability for Pharmacology and Toxicology Indication: Treatment of patients with castration-resistant prostate cancer who have received prior docetaxe(b) (4) Non-clinical pharmacology and toxicology studies to support
    [Show full text]
  • The Effect of F877L and T878A Mutations on Androgen Receptor
    Published OnlineFirst May 16, 2016; DOI: 10.1158/1535-7163.MCT-15-0892 Cancer Biology and Signal Transduction Molecular Cancer Therapeutics The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide Stefan Prekovic1, Martin E.van Royen2, Arnout R.D.Voet3,4, Bart Geverts2, Rene Houtman5, Diana Melchers5, Kam Y.J. Zhang3, Thomas Van den Broeck1,6, Elien Smeets1, Lien Spans7, Adriaan B. Houtsmuller2,8, Steven Joniau6, Frank Claessens1, and Christine Helsen1 Abstract Treatment-induced mutations in the ligand-binding domain that lead to a decrease in steric clashes for enzalutamide. of the androgen receptor (AR) are known to change antagonists Ligand-binding assays confirmed that the F877L mutation into agonists. Recently, the F877L mutation has been described leads to an increase in relative binding affinity for enzaluta- to convert enzalutamide into an agonist. This mutation was mide, but only the combination with the T878A mutation seen to co-occur in the endogenous AR allele of LNCaP cells, resulted in a strong agonistic activity. This correlated with next to the T878A mutation. Here, we studied the effects of changes in coregulator recruitment and chromatin interactions. enzalutamide on the F877L and T878A mutants, as well as Our data show that enzalutamide is only a very weak partial the double-mutant AR (F877L/T878A). Molecular modeling agonist of the AR F877L, and a strong partial agonist of the revealed favorable structural changes in the double-mutant AR double-mutant AR. Mol Cancer Ther; 15(7); 1702–12. Ó2016 AACR. Introduction chemotherapy by a median of 4.8 months in comparison with the placebo group (5).
    [Show full text]
  • Molecular and Preclinical Pharmacology of Nonsteroidal Androgen Receptor Ligands
    Molecular and Preclinical Pharmacology of Nonsteroidal Androgen Receptor Ligands Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Amanda Jones, M.S. Graduate Program in Pharmacy The Ohio State University 2010 Dissertation Committee: James T. Dalton, Advisor Thomas D. Schmittgen William L. Hayton Robert W. Brueggemeier Copyright by Amanda Jones 2010 Abstract The androgen receptor (AR) is critical for the growth and development of secondary sexual organs, muscle, bone and other tissues, making it an excellent therapeutic target. Ubiquitous expression of AR impedes the ability of endogenous steroids to function tissue selectively. In addition to the lack of tissue selectivity, clinical use of testosterone is limited due to poor bioavailability and pharmacokinetic problems. Our lab, in the last decade, discovered and developed tissue selective AR modulators (SARMs) that spare androgenic effects in secondary sexual organs, but demonstrate potential to treat muscle wasting diseases. This work reveals the discovery of next generation SARMs to treat prostate cancer and mechanistically characterize a prospective SARM in muscle and central nervous system (CNS). Prostate cancer relies on the AR for its growth, making it the primary therapeutic target in this disease. However, prolonged inhibition, with commercially available AR antagonists, leads to the development of mutations in its ligand binding domain resulting in resistance. Utilizing the crystal structure of AR-wild-type and AR-W741L mutant, we synthesized a series of AR pan- antagonists (that inhibit both wild-type and mutant ARs). Structure activity relationship studies indicate that sulfonyl and amine linkages of the aryl propionamide pharmacophore are important for the antagonist activity.
    [Show full text]
  • High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride As a Selective and Competitive Antago
    cells Article High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor 1,2, 1,2,3, 1,2 1,2 Hadjer Dellal y, Abdelhay Boulahtouf y, Elina Alaterre , Alice Cuenant , Marina Grimaldi 1,2, William Bourguet 2,4 ,Céline Gongora 1,2, Patrick Balaguer 1,2,* and Philippe Pourquier 1,2,* 1 IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, F-34298 Montpellier, France; [email protected] (H.D.); [email protected] (A.B.); [email protected] (E.A.); [email protected] (A.C.); [email protected] (M.G.); [email protected] (C.G.) 2 Université de Montpellier, F-34298 Montpellier, France; [email protected] 3 Institut régional du Cancer de Montpellier, F-34298 Montpellier, France 4 Centre de Biochimie Structurale, CNRS, INSERM, Université de Montpellier, F-34298 Montpellier, France * Correspondence: [email protected] (P.B.); [email protected] (P.P.); Tel.: +33-4-67-61-24-09 (P.B.); +33-4-66-68-32-31 (P.P.); Fax: +33-4-67-61-23-37 (P.B.); +33-4-66-68-37-02 (P.P.) H.D. and A.B. contributed equally. y Received: 6 May 2020; Accepted: 11 June 2020; Published: 16 June 2020 Abstract: Prostate cancer is the most commonly diagnosed malignancy in men. Its growth mainly relies on the activity of the androgen receptor (AR), justifying the use of androgen deprivation therapy as a gold standard treatment for the metastatic disease.
    [Show full text]
  • Mutation Based Resistance to Antiandrogens in Prostate Cancer
    Mutation Based Resistance to Antiandrogens in Prostate Cancer by Minna Delarae Balbas A Dissertation Presented to the Faculty of the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy New York, NY May, 2013 Charles L. Sawyers, MD Date Dissertation Mentor Copyright by Minna Delarae Balbas 2013 Abstract Androgen receptor (AR) signaling plays a crucial role in the growth and progression of prostate cancer. Current therapies for prostate cancer rely on this dependence and aim to disrupt AR signaling through androgen deprivation and the use of AR antagonists (antiandrogens). While this is usually an effective treatment initially, most prostate tumors eventually regain the ability to grow. Reactivation of AR signaling has been implicated in resistance, often through overexpression or mutation of the androgen receptor. Several AR mutations have been described that broaden ligand specificity or convert AR antagonists into agonists of the mutant receptor. These mutations alter the conformation of antiandrogen-bound AR, such that the antiandrogen now activates the receptor. The second-generation antiandrogen enzalutamide (formerly MDV3100) recently received FDA approval for patients with castration resistant prostate cancer. Despite its success, the duration of patient response is often limited. To prospectively identify AR mutations that might confer resistance to enzalutamide, we developed and performed a reporter-based mutagenesis screen using an AR-regulated EGFP reporter and randomly mutagenized AR cDNA library. After several rounds of enzalutamide exposure and FACS- sorting, we enriched a population of cells that maintain EGFP expression in the presence of drug.
    [Show full text]
  • Product Monograph Casodex®
    PRODUCT MONOGRAPH Pr CASODEX® bicalutamide tablets 50mg Tablets Non-Steroidal Antiandrogen AstraZeneca Canada Inc. Date of Revision: 1004 Middlegate Road July 13, 2017 Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca Control No. 205811 CASODEX® is a registered trademark of AstraZeneca UK Limited, used under license by AstraZeneca Canada Inc. COPYRIGHT 1995-2017 ASTRAZENECA CANADA INC. Page 1 of 32 TABLE OF CONTENTS TABLE OF CONTENTS .........................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION......................................................................3 INDICATIONS AND CLINICAL USE ...........................................................................3 CONTRAINDICATIONS.................................................................................................3 WARNINGS AND PRECAUTIONS ...............................................................................4 ADVERSE REACTIONS .................................................................................................8 DRUG INTERACTIONS ...............................................................................................12 DOSAGE AND ADMINISTRATION ...........................................................................13 OVERDOSAGE..............................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY..........................................................14
    [Show full text]
  • Resistance to Second Generation Antiandrogens in Prostate Cancer: Pathways and Mechanisms
    Verma et al. Cancer Drug Resist 2020;3:742-61 Cancer DOI: 10.20517/cdr.2020.45 Drug Resistance Review Open Access Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms Shiv Verma1,2, Kumari Sunita Prajapati3, Prem Prakash Kushwaha3, Mohd Shuaib3, Atul Kumar Singh3, Shashank Kumar3, Sanjay Gupta1,2,4,5,6 1Department of Urology, Case Western Reserve University, Cleveland, OH 44106, USA. 2The Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA. 3School of Basic and Applied Sciences, Department of Biochemistry and Microbial Sciences, Central University of Punjab, Bathinda 151001, India. 4Department of Nutrition, Case Western Reserve University, Cleveland, OH 44106, USA. 5Divison of General Medical Sciences, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA. 6Department of Urology, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106, USA. Correspondence to: Prof. Sanjay Gupta, The James and Eilleen Dicke Laboratory, Department of Urology, Case Western Reserve University, 2109 Adelbert Road, Wood Research Tower-RTG01, Cleveland, OH 44106, USA. E-mail: [email protected] How to cite this article: Verma S, Prajapati KS, Kushwaha PP, Shuaib M, Singh AK, Kumar S, Gupta S. Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms. Cancer Drug Resist 2020;3:742-61. http://dx.doi.org/10.20517/cdr.2020.45 Received: 24 Jun 2020 First Decision: 31 Jul 2020 Revised: 3 Aug 2020 Accepted: 6 Aug 2020 Available online: 17 Sep 2020 Academic Editor: Vincent C. O. Njar Copy Editor: Cai-Hong Wang Production Editor: Jing Yu Abstract Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling continues to be the mainstay treatment of advanced-stage prostate cancer.
    [Show full text]
  • Promotion of Agonist Activity of Antiandrogens by the Androgen Receptor Coactivator, ARA70, in Human Prostate Cancer DU145 Cells
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 7379–7384, June 1998 Biochemistry Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells HIROSHI MIYAMOTO*, SHUYUAN YEH*, GEORGE WILDING†, AND CHAWNSHANG CHANG*†‡ *George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Biochemistry, University of Rochester Medical Center, Rochester, NY 14642; and †University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792 Communicated by Jack Gorski, University of Wisconsin-Madison, Madison, WI, April 15, 1998 (received for review January 9, 1998) ABSTRACT Although hormone therapy with antiandro- androgens (13–15). However, the mechanisms responsible for gens has been widely used for the treatment of prostate cancer, androgen independence and the antiandrogen withdrawal some antiandrogens may act as androgen receptor (AR) syndrome remain unclear. agonists that may result in antiandrogen withdrawal syn- In the present study, we investigated the influence of six drome. The molecular mechanism of this agonist response, antiandrogens and related compounds on AR transcriptional however, remains unclear. Using mammalian two-hybrid as- activity. Classic steroid binding assays have suggested these say, we report that antiandrogens, hydroxyflutamide, bicalu- compounds can inhibit the binding of androgens to the AR in tamide (casodex), cyproterone acetate, and RU58841, and target cells. Three of these antiandrogens have been used other compounds such as genistein and RU486, can promote clinically in the treatment of prostate cancer: CPA, HF, and the interaction between AR and its coactivator, ARA70, in a bicalutamide (casodex). CPA is a synthetic steroidal antian- dose-dependent manner. The chloramphenicol acetyltrans- drogen and one of the first antiandrogens used clinically in ferase assay further demonstrates that these antiandrogens Europe (16); however, it has many side effects (17).
    [Show full text]